Altis Biosystems, Inc.
Durham, NC
- UEI
- YNJPFV6C18Z9
- CAGE
- 7FS03
- Primary NAICS
- 238990 All Other Specialty Trade Contractors
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6 Davis Dr #159, Durham, NC 27709, USA
- Website
- altisbiosystems.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Intero Biosystems Inc. | Aurora, CO | 325414 Biological Product (except Diagnostic) Manufacturing |
| Insphero, Inc. | Portland, ME | 325414 Biological Product (except Diagnostic) Manufacturing |
| Xylyx Bio, Inc. | NY | — |
| Lena Biosciences, Inc. | Atlanta, GA | — |
| Mimetas US Inc. | Gaithersburg, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Altis Biosystems, Inc. is a biotechnology company that has developed proprietary technologies to generate in vitro models of human organ systems, like the gastrointestinal tract, for applications in drug discovery and development. According to its website, Altis utilizes primary cell sources and stem cell-derived tissues to produce physiologically relevant human models.
Through various prime and sub federal grants from the National Institutes of Health, Altis Biosystems has provided scientific research and prototypes related to high-throughput compound screening platforms and assays utilizing its stem cell-derived gastrointestinal models. For example, Altis received a $343,297 NCATS grant to develop an intestinal model for evaluating drug effects on lipid transport and chylomicron dynamics. A $913,659 NCATS award also funded Altis' optimization of a stem cell toxicity screening platform called STEMTOX to predict gastrointestinal side effects. Altis further delivered a mucus-producing gastrointestinal epithelium prototype and associated protocols under a $587,982 NIDDK grant. Additional NIH grants have also supported Altis' development of various reporter gene intestinal models, co-culture systems with immune cells, and 2D crypt platforms for assessing drug and toxicity impacts on intestinal stem cell health.
Quick answers
Is Altis Biosystems, Inc. registered in SAM.gov?
Yes. Altis Biosystems, Inc.'s SAM.gov registration is active through July 6, 2027.
What is Altis Biosystems, Inc.'s most recent federal award?
Altis Biosystems, Inc.'s most recent federal grant award is Metabolgut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated… (R43TR004549), from National Center for Advancing Translational Sciences (NIH), on September 1, 2023.
On GovTribe
See Altis Biosystems, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors